Epidemiology & Public Health

Epidemiology is the study of the distribution and determinants of health-related states and events in defined populations, and the application of that study to control health problems. Two phrases in that definition carry the whole field. Distribution means who gets a disease, where, and when - the counting and mapping of health. Determinants means why - the causes, risk factors, and protective factors that explain the pattern. Epidemiology is the basic science of public health: it supplies the evidence on which prevention and policy are built.

The population perspective

Clinical medicine asks, "What is wrong with this patient, and how do I treat them?" Public health asks, "Why do some populations have more disease than others, and how do we prevent it?" The unit of concern shifts from the individual to the population. This shift has a profound consequence known as the prevention paradox: a preventive measure that brings large benefit to a whole population may offer little to each participating individual. A small downward shift in the entire distribution of blood pressure prevents more strokes across a society than intensively treating only the few people with the very highest pressures, even though any one person feels almost nothing. Because most cases often arise from the large number of people at modest risk rather than the small number at extreme risk, public health frequently favors a population strategy alongside a high-risk strategy.

Public health and its core functions

Public health is what a society does collectively to assure the conditions in which people can be healthy. Its recognized core functions are assessment (measuring the health of populations, largely through epidemiology and surveillance), policy development (using that evidence to craft laws, programs, and guidelines), and assurance (making sure needed services are actually delivered). Its triumphs are largely invisible because they are absences: clean water and sanitation, vaccination, safer workplaces, tobacco control, motor-vehicle safety, and the control of infectious disease account for far more of the twentieth-century gain in life expectancy than clinical care did.

The epidemiologic triad and the levels of prevention

A classic model of disease causation is the epidemiologic triad: an agent (a microbe, a toxin, a nutrient deficiency), a host (the person, with their susceptibility), and an environment that brings the two together, with a vector often carrying the agent. Break any leg of the triad and transmission stops. Prevention is likewise layered. Primary prevention stops disease before it starts (vaccination, seatbelts); secondary prevention detects disease early when it is still treatable (screening); and tertiary prevention limits disability once disease is established (rehabilitation, managing complications).

Descriptive and analytic epidemiology

Epidemiology proceeds in two broad modes. Descriptive epidemiology characterizes health by person, place, and time - who is affected, where, and when - generating hypotheses. Analytic epidemiology then tests those hypotheses with comparison groups, asking whether an exposure is truly associated with an outcome. The rest of this course builds the analytic toolkit, but it begins, in the next lesson, with the most basic task of all: counting how much disease there is.

Before you can study causes, you must count cases. But a raw count ("500 cases of disease") is nearly meaningless without a denominator - the population at risk and the time over which cases arose. Epidemiology therefore expresses disease as a rate or proportion, always cases divided by an appropriate population. The two great families of frequency measures are incidence (new cases) and prevalence (existing cases).

Incidence: the rate of new disease

Incidence measures new cases arising in a population that was initially disease-free. It comes in two forms. The incidence proportion (also called cumulative incidence or the risk) is the number of new cases divided by the number of people at risk at the start, over a stated period. If 900 disease-free people are followed for one year and 30 develop the disease, the incidence proportion is 30 divided by 900, which equals 0.033, or 33 per 1,000 per year. It is a probability, so it ranges from 0 to 1 and always needs a time frame attached.

When people are followed for different lengths of time, or enter and leave, we use the incidence rate (or incidence density): new cases divided by the total person-time at risk. Person-time sums each individual's time under observation. If a study accumulates 480 person-years and observes 12 new cases, the incidence rate is 12 divided by 480, which equals 0.025 per person-year, or 25 per 1,000 person-years. Because its denominator is time, an incidence rate has no upper bound of 1 and cannot itself be read as a simple probability.

Prevalence: the burden of existing disease

Prevalence is the proportion of a population that has the disease at a point in time (point prevalence) or over an interval (period prevalence). It counts old and new cases alike. If 240 of 1,200 people surveyed have the condition today, the point prevalence is 240 divided by 1,200, which equals 0.20, or 20 percent. Prevalence is a snapshot of burden - useful for planning services and allocating resources - but because it mixes new cases with survival, it is a poor measure of the risk of getting a disease.

How incidence and prevalence relate

Prevalence is fed by incidence and drained by recovery and death. In a steady state, the relationship is approximately:

Prevalence ≈ Incidence × Duration

A disease with low incidence but long duration (for example, a chronic, non-fatal condition) can have high prevalence, while a common but brief illness (a cold) has high incidence yet low prevalence at any moment. Worked example: if the incidence is 0.02 per year and the average duration is 5 years, the approximate prevalence is 0.02 times 5, which equals 0.10, or 10 percent. This single relationship explains a common trap: a rising prevalence can mean more people are getting sick (higher incidence) or that patients are living longer with disease (longer duration, often a sign of better treatment) - opposite stories with the same number.

Measure	Numerator	Denominator	Best for
Incidence proportion (risk)	New cases	People at risk at start	Probability of developing disease
Incidence rate	New cases	Person-time at risk	Speed of new disease with varying follow-up
Prevalence	All existing cases	Total population	Burden of disease for planning

The central question of analytic epidemiology is comparative: do exposed people develop disease more often than unexposed people? Almost every measure of association is read off a single tool, the two-by-two table, which cross-classifies each person by exposure (yes or no) and disease (yes or no). By long convention the cells are labeled a, b, c, and d:

	Disease +	Disease -	Total
Exposed +	a	b	a + b
Exposed -	c	d	c + d

Here a is exposed people with disease, b is exposed without disease, c is unexposed with disease, and d is unexposed without disease. Learning to read this table fluently is the single most useful skill in the course, because the design you used determines which measure the table can give you.

Risk in each group

When you have followed a defined group forward (a cohort), you can compute the risk (incidence proportion) in each row. The risk in the exposed is a divided by (a + b). The risk in the unexposed is c divided by (c + d). These two numbers are the raw material of comparison.

Relative risk (the risk ratio)

The relative risk (RR), or risk ratio, is simply the risk in the exposed divided by the risk in the unexposed:

RR = [a / (a + b)] ÷ [c / (c + d)]

Its interpretation is direct. RR = 1 means the exposed and unexposed have equal risk - no association. RR > 1 means exposure is associated with more disease (a possible risk factor). RR < 1 means exposure is associated with less disease (a possible protective factor, as we hope for a vaccine). An RR of 3 means the exposed have three times the risk; an RR of 0.5 means the exposed have half the risk.

Worked example

Suppose we follow 3,000 smokers and 3,000 non-smokers for ten years for a heart-disease outcome. Among smokers, 90 develop disease; among non-smokers, 30 do. The table is:

	Disease +	Disease -	Total
Smokers	90	2,910	3,000
Non-smokers	30	2,970	3,000

Risk in the exposed (smokers) = 90 / 3,000 = 0.030, or 30 per 1,000. Risk in the unexposed = 30 / 3,000 = 0.010, or 10 per 1,000. Therefore:

RR = 0.030 / 0.010 = 3.0

Smokers in this study had three times the risk of heart disease compared with non-smokers. Note that the relative risk answers a proportional question ("how many times the risk?"); it says nothing by itself about how much disease that represents in absolute terms - a gap the next lesson fills with attributable risk. Note too that you could only compute an RR here because the cohort design gave you true risks in each group; a case-control study, where you choose how many cases and controls to enroll, cannot yield a valid RR, which is why the odds ratio exists.

The relative risk is intuitive, but it requires knowing the true risk in each group, which means following a cohort forward. Many important questions - especially about rare diseases - are studied instead with the case-control design, which starts from people who already have the disease (cases) and compares them with people who do not (controls), looking backward at exposure. In that design you cannot compute a risk, because you, the investigator, decided how many cases and controls to enroll. The measure that works is the odds ratio.

Odds versus probability

The odds of an event is the probability it happens divided by the probability it does not - the ratio of the number with the event to the number without it. If 3 of 4 people are exposed, the probability of exposure is 3/4 = 0.75, while the odds of exposure is 3 to 1, or 3. Odds and probability carry the same information in different form, and odds have a mathematical convenience that makes them natural for case-control data.

The odds ratio

The odds ratio (OR) compares the odds of exposure in cases with the odds of exposure in controls. Remarkably, using the a, b, c, d cells this reduces to the simple cross-product:

OR = (a × d) ÷ (b × c)

Its interpretation mirrors the relative risk: OR = 1 means no association, OR > 1 means exposure is more common in cases (a risk factor), and OR < 1 means exposure is less common in cases (protective).

Worked example

Investigators enroll 200 lung-cancer cases and 200 healthy controls and ask about past exposure to a workplace chemical. Among the 200 cases, 120 were exposed and 80 were not. Among the 200 controls, 60 were exposed and 140 were not. The table is:

	Cases (Disease +)	Controls (Disease -)
Exposed +	a = 120	b = 60
Exposed -	c = 80	d = 140

Applying the cross-product:

OR = (120 × 140) ÷ (60 × 80) = 16,800 ÷ 4,800 = 3.5

The odds of the chemical exposure were 3.5 times higher in cases than in controls, evidence that the exposure is associated with the cancer. Notice we never computed a risk - only odds of exposure - which is exactly why the odds ratio is the correct measure when the sampling is done by disease status.

When the odds ratio approximates the relative risk

A crucial fact makes case-control studies so valuable: when the disease is rare (roughly under 10 percent in the population), the odds ratio closely approximates the relative risk. This is the rare disease assumption. Consider a population table with a = 10, b = 990, c = 5, d = 995. The relative risk is [10/1000] / [5/1000] = 2.0, and the odds ratio is (10 × 995) / (990 × 5) = 9,950 / 4,950 = 2.01 - essentially identical. When disease is common the two diverge, with the OR exaggerating the RR, so a common-disease OR must be interpreted as an odds ratio, not casually reported as "times the risk."

Relative risk tells you how strongly an exposure and a disease are linked. But public health also needs to know how much disease an exposure actually causes - the absolute impact. That is the job of the attributable risk family of measures, which use subtraction rather than division.

Attributable risk (the risk difference)

The attributable risk (AR), also called the risk difference or excess risk, is the risk in the exposed minus the risk in the unexposed:

AR = [a / (a + b)] - [c / (c + d)]

It estimates the amount of disease among the exposed that is attributable to the exposure, assuming the association is causal. Using our smoking cohort (risk in smokers 0.030, risk in non-smokers 0.010), the attributable risk is 0.030 - 0.010 = 0.020, or 20 excess cases per 1,000 smokers. In words: of every 1,000 smokers, about 20 heart-disease cases would not have occurred without smoking. This absolute number is what shapes prevention, because it says how many cases could actually be prevented.

Relative and absolute measures can tell different stories

A large relative risk on a rare outcome can mean few actual cases, while a modest relative risk on a common outcome can mean many. Suppose exposure A triples a rare risk from 1 to 3 per 100,000 (RR = 3, but AR = only 2 per 100,000), while exposure B raises a common risk from 100 to 150 per 100,000 (RR = 1.5, but AR = 50 per 100,000). Exposure B, with the smaller relative risk, causes twenty-five times more excess disease. This is why reporting a relative risk alone can badly mislead, and why absolute measures belong beside it.

Attributable risk percent

The attributable risk percent (AR%) expresses the excess as a fraction of the total risk in the exposed:

AR% = (Risk in exposed - Risk in unexposed) ÷ Risk in exposed × 100

For the smokers: (0.030 - 0.010) / 0.030 × 100 = 66.7 percent. Among exposed people who got the disease, about two-thirds of their risk is attributable to the exposure. Equivalently, using the relative risk, AR% = (RR - 1) / RR × 100 = (3 - 1) / 3 × 100 = 66.7 percent, the same answer.

Population attributable risk

Public health cares not only about the exposed but about the whole population, where impact depends on how common the exposure is. The population attributable risk percent (PAR%) is the fraction of disease in the entire population that would be eliminated if the exposure were removed. A moderately harmful exposure that is very widespread (say, physical inactivity) can carry a larger population attributable risk than a highly dangerous but rare one. This is precisely the calculation that guides where public health should spend its effort: not only on the most dangerous exposures, but on those whose combination of risk and prevalence produces the most preventable disease.

Study designs form a ladder from simply describing what is seen to rigorously testing causes. The lower rungs generate hypotheses cheaply; the higher rungs test them convincingly. Choosing wisely means matching the design to the question, the disease, and the resources at hand.

Descriptive designs

A case report describes a single striking patient; a case series describes several. They cannot establish cause because there is no comparison group, but they are often the first alarm - clusters of rare pneumonia in case reports first signaled the AIDS epidemic. An ecological study compares whole groups rather than individuals, correlating, for example, average fat intake against heart-disease rates across countries. Ecological data are easy to obtain but carry a specific danger.

The ecological fallacy

The ecological fallacy is the error of drawing conclusions about individuals from group-level data. If countries with higher average salt intake have higher stroke rates, it does not follow that the high-salt individuals within each country are the ones having strokes - the association at the group level may not hold at the individual level. Ecological studies suggest hypotheses; they do not confirm individual-level causes.

Cross-sectional studies

A cross-sectional study measures exposure and disease at the same point in time in a sample of individuals - a snapshot, like a single survey. It is the natural design for measuring prevalence ("what fraction of adults have hypertension right now?") and for describing the health of a population. Because it captures everyone at once, it is fast and relatively cheap, and it can examine many exposures and outcomes together.

Its great limitation is temporal ambiguity: because exposure and disease are measured simultaneously, you usually cannot tell which came first. If a survey finds that people who exercise less are more depressed, does inactivity cause depression, or does depression reduce activity? The snapshot cannot say. Cross-sectional studies also tend to over-represent long-lasting cases and miss those who already recovered or died (prevalence-incidence bias), so they describe burden well but test causes poorly.

Design	Comparison group?	Establishes time order?	Main use
Case report / series	No	No	First description of rare events
Ecological	Groups	No	Hypothesis generation (risk of ecological fallacy)
Cross-sectional	Individuals, one time point	No	Prevalence and population description

The two workhorse observational analytic designs are the cohort study and the case-control study. Both compare exposed and unexposed experience, but they start from opposite ends and suit opposite situations. Understanding their logic is central to reading almost any epidemiologic paper.

Cohort studies: exposure to outcome

A cohort study classifies people by exposure first and then follows them forward in time to see who develops the disease. Because it observes incidence directly, it yields risks and therefore the relative risk and attributable risk. A cohort can be prospective (assemble the cohort now and follow into the future) or retrospective (use existing records to reconstruct a cohort defined by past exposure and follow forward from then to now). Cohorts are excellent for a rare exposure (you can deliberately enroll exposed people, such as workers at a particular plant) and for studying multiple outcomes of a single exposure. Their weaknesses are cost, long duration, and loss to follow-up - people drop out, and if dropout is related to both exposure and outcome, results distort.

Case-control studies: outcome to exposure

A case-control study starts from the disease first, assembling cases (people with the disease) and controls (comparable people without it), then looks backward to compare past exposure. Because sampling is by disease status, it yields the odds ratio, not the relative risk. Case-control studies shine for a rare disease (you start with the scarce cases instead of waiting for them to appear) and for diseases with a long latency, and they are fast and inexpensive. Their central challenge is bias: recall bias (cases remember exposures more keenly than controls) and selection bias in choosing controls can both mislead. Choosing controls that come from the same population that produced the cases is the hardest part of a good case-control study.

Feature	Cohort study	Case-control study
Starts from	Exposure	Disease
Direction	Forward to outcome	Backward to exposure
Measure of association	Relative risk (and attributable risk)	Odds ratio
Best for	Rare exposures; multiple outcomes	Rare diseases; long latency
Key weakness	Cost, time, loss to follow-up	Recall and selection bias

Choosing the design

The choice follows the question. To study many possible effects of a single unusual exposure - say the health of astronauts - a cohort is natural. To study a rare cancer with dozens of suspected causes, a case-control study is far more efficient. A memorable heuristic: cohorts are good for rare exposures, case-control studies are good for rare diseases. The nested case-control study combines their strengths by drawing cases and controls from within an existing cohort, keeping the efficiency of case-control sampling while retaining the cohort's high-quality, pre-collected exposure data.

All the designs so far are observational: the investigator watches exposures that people chose or encountered on their own. The randomized controlled trial (RCT) is experimental - the investigator assigns the exposure (usually a treatment or preventive intervention) by chance. This one feature makes the RCT the strongest single design for establishing that an intervention causes an effect, and the foundation of evidence-based medicine.

Why randomization is powerful

In observational studies, people who take a treatment often differ systematically from those who do not - they may be healthier, wealthier, or more health-conscious - and these differences (confounders) can masquerade as effects. Randomization, assigning each participant to a group by chance, tends to distribute all characteristics, both those we know and those we have never thought of, evenly between the groups. That is randomization's unique gift: it balances even unknown confounders, something no amount of statistical adjustment in an observational study can guarantee. If the groups then differ in outcome, the difference can be attributed to the intervention.

The machinery of a good trial

• Control group - a comparison arm receiving a placebo (an inert look-alike) or the current standard of care, so the intervention's effect can be isolated from the natural course of disease and the placebo effect.
• Blinding (masking) - keeping participants, and ideally the investigators and outcome assessors, unaware of who received which treatment. A double-blind trial blinds both patient and researcher, preventing expectations from coloring behavior or assessment.
• Intention-to-treat analysis - analyzing every participant in the group to which they were randomized, regardless of whether they completed the assigned treatment. This preserves the balance randomization created and gives a realistic estimate of the intervention's effect in practice; analyzing only those who complied can reintroduce bias.

Strengths, limits, and ethics

The RCT's strength is unmatched control of confounding and clear temporal order, so it sits atop the hierarchy of evidence for treatment questions. But it has real limits. Trials are expensive and often short. Their tightly selected participants may not resemble ordinary patients, limiting generalizability (external validity). And crucially, RCTs are bound by ethics: you cannot randomize people to a suspected harm. No one may assign volunteers to smoke or to be exposed to a toxin, which is exactly why the causal case against such exposures rests on observational evidence weighed by judgment - the subject of the next module. The principle of equipoise, genuine uncertainty about which arm is better, is what makes randomizing patients ethical in the first place.

Whenever a study reports an association, three rival explanations must be excluded before believing it reflects a true effect: bias, confounding, and chance. This lesson takes the first. Bias is any systematic error in the design, conduct, or analysis of a study that produces a wrong estimate of the association. The word systematic is essential: unlike random error (chance), bias pushes results consistently in one direction, and - a point students often miss - a larger sample does not fix bias. It only makes a biased estimate more precisely wrong. Bias comes in two broad families.

Selection bias

Selection bias arises when the people included in the study, or retained in it, differ systematically from the target population in ways related to both exposure and outcome, so the study groups are not comparable. Examples include:

• Healthy worker effect - employed people are healthier than the general population, so a workforce may appear to have lower disease rates than it truly causes.
• Berkson's bias - using hospitalized controls, who are themselves sick, can distort exposure comparisons.
• Loss to follow-up (attrition) bias - if dropout in a cohort is related to both exposure and outcome, the remaining sample is skewed.
• Self-selection (volunteer) bias - volunteers differ from non-volunteers in health and behavior.

Information bias

Information bias arises from systematic error in measuring exposure or outcome - the data themselves are mismeasured. Key forms include:

• Recall bias - cases remember past exposures more completely than controls (a classic hazard of case-control studies).
• Interviewer bias - an interviewer who knows a subject's disease status probes exposures differently.
• Misclassification - errors in sorting people as exposed or diseased. Non-differential misclassification (errors unrelated to the other variable) usually blurs an association toward the null, weakening it; differential misclassification (errors that differ by group) can push an association in either direction, sometimes creating one that does not exist.

Guarding against bias

Because bias is built into the study's structure, it must be prevented by design - it cannot be removed afterward the way confounding sometimes can. Sound sampling, objective and identically applied measurements, blinding of assessors, choosing controls from the same source population as cases, and minimizing dropout are the defenses. The critical reader's habit is to ask, for every reported association: could the way people were selected, or the way data were collected, have manufactured this result?

Confounding is the mixing of the effect of the exposure of interest with the effect of another variable, producing a distorted, sometimes entirely spurious, association. It is the reason correlation is not causation, and recognizing it is a defining skill of the epidemiologist.

What makes a variable a confounder

A variable is a confounder only if it meets three conditions:

1. It is associated with the exposure.
2. It is an independent risk factor for the outcome (associated with the disease apart from the exposure).
3. It is not on the causal pathway between exposure and outcome (it is not a step by which the exposure causes the disease).

The classic illustration: a study finds that coffee drinkers have more lung cancer. But coffee drinkers are also more likely to smoke, and smoking causes lung cancer. Smoking is associated with the exposure (coffee), is an independent cause of the outcome (lung cancer), and is not a step by which coffee might cause cancer. Smoking confounds the coffee-cancer association, creating an apparent link that largely vanishes once smoking is accounted for. Age and sex confound so many associations that they are adjusted for almost by reflex.

Confounding is not effect modification

These two are often confused. Confounding is a nuisance to be removed - a distortion of the true effect. Effect modification (interaction) is a real biological finding to be reported: the exposure's effect genuinely differs across levels of a third variable. If a drug lowers risk in younger patients but not older ones, age is an effect modifier, and reporting a single overall effect would hide the truth. The test is practical: if adjusting for the third variable changes the estimate, suspect confounding; if the effect is truly different in each subgroup, that is effect modification, and the subgroup results should be presented separately.

Controlling confounding

Unlike bias, confounding can be addressed at two stages.

Stage	Method	How it works
Design	Randomization	Balances all confounders, known and unknown (RCTs only)
Design	Restriction	Admit only one level of the confounder (e.g. only non-smokers)
Design	Matching	Pair exposed and unexposed (or cases and controls) on the confounder
Analysis	Stratification	Analyze within strata of the confounder, then pool
Analysis	Multivariable adjustment	Use regression to statistically hold confounders constant

The great limitation of every analytic method is that you can only adjust for confounders you have measured. Residual confounding from unmeasured or imperfectly measured variables always lurks in observational studies - which is precisely why randomization, the one method that handles the unknown, is so prized.

Suppose a well-conducted study reports an association, and bias, confounding, and chance have been reasonably excluded. Is the exposure a cause of the disease? Epidemiology rarely proves causation from a single study the way a laboratory experiment might. Instead, causal judgment is reached by weighing an entire body of evidence against a set of considerations proposed in 1965 by the British statistician Sir Austin Bradford Hill. These are not a checklist to be scored, and no single one is necessary or sufficient - they are viewpoints that, taken together, strengthen or weaken the case for causation.

The nine viewpoints

1. Strength of association - a large relative risk is harder to explain away by undetected bias or confounding than a small one.
2. Consistency - the association is found repeatedly, by different investigators, in different populations, with different methods.
3. Specificity - one exposure leads to one outcome. This is the weakest viewpoint, since many exposures have multiple effects, and its absence does not argue against cause.
4. Temporality - the exposure precedes the disease. This is the one viewpoint that is absolutely required: a cause must come before its effect.
5. Biological gradient (dose-response) - more exposure produces more disease, as smoking more cigarettes raises lung-cancer risk further.
6. Plausibility - a credible biological mechanism exists (though this is limited by the science of the day).
7. Coherence - the causal interpretation does not conflict with what is known about the disease's natural history and biology.
8. Experiment - removing the exposure reduces the disease, as when quitting smoking lowers risk or removing a contaminated water source ends an outbreak.
9. Analogy - established causal relationships for similar exposures make a new one more believable.

Temporality is non-negotiable

Of all nine, only temporality is a strict requirement. Strength, consistency, and dose-response are powerful when present, but the exposure must come first - which is why cross-sectional studies, unable to fix time order, cannot establish cause on their own, and why longitudinal designs are so valued.

The viewpoints in action: smoking and lung cancer

The mid-twentieth-century case that smoking causes lung cancer, built entirely from observational data because randomizing people to smoke was unthinkable, illustrates the viewpoints beautifully. The association was strong (heavy smokers had many times the risk), consistent across dozens of studies and countries, showed a clear dose-response gradient, respected temporality (smoking preceded cancer by years), was biologically plausible and coherent with carcinogens in smoke, and satisfied the experiment viewpoint because quitting lowered risk. No one study proved it; the convergence did. This is how epidemiology reasons its way from association to cause, and it is the intellectual heart of the discipline.

Secondary prevention depends on screening: applying a test to apparently healthy people to detect disease early. To evaluate any test - screening or diagnostic - epidemiologists compare its result against the truth, established by a gold standard, in a familiar two-by-two table. This time the rows are the test result and the columns are true disease status:

	Disease + (truth)	Disease - (truth)
Test +	True Positive (TP)	False Positive (FP)
Test -	False Negative (FN)	True Negative (TN)

Sensitivity and specificity: properties of the test

Sensitivity is the proportion of people with the disease whom the test correctly calls positive: TP / (TP + FN). A highly sensitive test rarely misses disease, so a negative result from it is reassuring (a good rule-out test). Specificity is the proportion of people without the disease whom the test correctly calls negative: TN / (TN + FP). A highly specific test rarely falsely alarms, so a positive result from it is convincing (a good rule-in test). Crucially, sensitivity and specificity are relatively stable properties of the test itself and do not change with disease prevalence.

Worked example

A new screening test is applied to 1,000 people, of whom 100 truly have the disease (10 percent prevalence). The test correctly flags 90 of the diseased and misses 10; among the 900 healthy people it correctly clears 720 and falsely alarms 180. The table:

	Disease +	Disease -	Total
Test +	TP = 90	FP = 180	270
Test -	FN = 10	TN = 720	730
Total	100	900	1,000

Sensitivity = 90 / (90 + 10) = 90 / 100 = 0.90 = 90 percent.
Specificity = 720 / (720 + 180) = 720 / 900 = 0.80 = 80 percent.

Predictive values: what a result means for a patient

A patient does not ask "how sensitive is the test"; they ask "I tested positive - do I have the disease?" That is the positive predictive value (PPV): the proportion of test-positives who truly have the disease, TP / (TP + FP). The negative predictive value (NPV) is the proportion of test-negatives who are truly disease-free, TN / (TN + FN). From the table:

PPV = 90 / (90 + 180) = 90 / 270 = 0.333 = 33.3 percent.
NPV = 720 / (720 + 10) = 720 / 730 = 0.986 = 98.6 percent.

Strikingly, even though this test is 90 percent sensitive, only one in three positives actually has the disease. That gap - between how good the test is and what a positive means - is governed by prevalence, the subject of the next lesson.

The sensitivity-specificity trade-off

For any test with a numeric cutoff, moving the threshold trades one property for the other. Loosening the cutoff to catch more true cases raises sensitivity but lowers specificity (more false alarms); tightening it does the reverse. There is no free lunch. Which way to lean depends on the stakes: a screening test for a dangerous, treatable disease favors high sensitivity (do not miss cases), accepting more false positives that a confirmatory test will sort out.

The most counterintuitive fact in test evaluation is this: the same test, with fixed sensitivity and specificity, gives very different answers to the patient depending on how common the disease is. Sensitivity and specificity belong to the test; predictive values belong to the population. Understanding why is essential to interpreting any positive result honestly.

Why prevalence drives predictive value

When a disease is rare, the vast majority of people tested are healthy, so even a small false-positive rate generates a large number of false positives - which can swamp the true positives and drive the positive predictive value down. When a disease is common, positives are much more likely to be real. Consider a test with sensitivity 95 percent and specificity 90 percent applied to 100,000 people at three different prevalences:

Prevalence	True positives	False positives	PPV	NPV
1 percent (rare)	950	9,900	8.8 percent	99.9 percent
10 percent	9,500	9,000	51.4 percent	99.4 percent
50 percent (common)	47,500	5,000	90.5 percent	94.7 percent

At 1 percent prevalence, a positive result is right less than 1 time in 10, because the 9,900 false positives (10 percent of the 99,000 healthy people) dwarf the 950 true positives - yet the identical test at 50 percent prevalence gives a positive that is right 9 times in 10. This is why screening the general (low-risk) population for a rare disease produces mostly false alarms, and why we target screening to higher-risk groups, where prevalence, and thus PPV, is higher. It is also the mathematics behind the anxiety of a positive result on a rare-disease screen: most such positives are false.

What makes screening worthwhile

Screening is not automatically good; a program must satisfy conditions long associated with Wilson and Jungner. The disease should be serious and reasonably common, with a recognizable early or latent stage, and its natural history understood. The test should be safe, acceptable, and sufficiently sensitive and specific for the setting. And, most important, there must be an effective treatment that works better when begun early - screening for an untreatable disease only lengthens the time a person knows they are ill.

Biases that make screening look better than it is

Evaluating screening is treacherous because two biases can make it appear to prolong life when it does not. Lead-time bias is the illusion of longer survival created simply by diagnosing disease earlier - the clock starts sooner, so measured survival looks longer even if death comes at the same moment. Length-time bias is the tendency of screening to preferentially catch slow-growing, indolent cases (which spend longer in a detectable phase), making screen-detected disease look more survivable than it is. Because of these traps, screening's real value must be judged by whether it lowers mortality in a randomized trial, not by comparing survival times of screened and unscreened patients.

Infectious disease epidemiology adds a feature no chronic disease has: one case can create another. Because cases are not independent, the mathematics of spread is distinctive, and controlling it means breaking chains of transmission.

The chain of infection

Transmission requires a linked chain: an agent, a reservoir where it lives (humans, animals, or the environment), a portal of exit, a mode of transmission, a portal of entry, and a susceptible host. Modes of transmission include direct contact, droplet, airborne, vehicle (food, water, blood), and vector-borne (mosquitoes, ticks). Every control measure works by breaking one link: killing the agent (disinfection), removing the reservoir, blocking transmission (masks, mosquito nets, hand hygiene), or protecting the susceptible host (vaccination). A person who harbors and spreads a pathogen without symptoms is an asymptomatic carrier, a link that makes some diseases especially hard to stop.

The basic reproduction number

The single most important quantity in infectious disease epidemiology is the basic reproduction number, R-naught (R₀): the average number of new infections produced by one infectious person in a completely susceptible population. Its value decides whether an epidemic grows or dies out:

• R₀ > 1: each case produces more than one new case, so the disease spreads and an epidemic can occur.
• R₀ = 1: each case replaces itself; the disease is endemic and stable.
• R₀ < 1: cases fail to replace themselves and the outbreak fades.

Measles is among the most contagious diseases known, with R₀ often cited around 12 to 18; seasonal influenza is much lower. As a population gains immunity, the effective reproduction number (R) falls below R₀, and control is achieved once R drops below 1.

Herd immunity

Herd immunity is the indirect protection that unimmunized people receive when enough of the surrounding population is immune that sustained transmission cannot occur - the pathogen simply cannot find enough susceptible hosts to keep chains going. The fraction that must be immune, the herd immunity threshold (Hc), follows directly from R₀:

Hc = 1 - (1 / R₀)

The more contagious the disease (higher R₀), the greater the share that must be immune. Worked values:

Disease example	R₀	Hc = 1 - 1/R₀
Lower-contagion illness	2	1 - 1/2 = 50 percent
Moderate-contagion illness	4	1 - 1/4 = 75 percent
Measles (highly contagious)	16	1 - 1/16 = 93.75 percent

This is why measles requires roughly 95 percent vaccination coverage to prevent outbreaks, while a less contagious disease needs far less. It also explains why coverage that slips even a few points can let a highly contagious disease return: once the immune fraction falls below Hc, R rises above 1 and transmission resumes.

When disease appears in excess of what is expected, public health mounts an outbreak investigation - epidemiology at its most urgent and practical. An outbreak or epidemic is the occurrence of cases clearly in excess of normal expectancy in an area; a pandemic is an epidemic spread over many countries or continents; and an endemic disease is one at its usual, baseline level in a population.

The steps of an investigation

Investigations follow a well-worn sequence, though steps often overlap and iterate:

1. Confirm the outbreak and verify the diagnosis - is there truly excess disease, and is the diagnosis correct?
2. Define a case - write an explicit case definition (clinical features plus limits of person, place, and time) so cases are counted consistently.
3. Find cases and count them - conduct systematic case-finding and record each case.
4. Describe by person, place, and time - the descriptive epidemiology, including the epidemic curve.
5. Develop hypotheses about the source and mode of transmission.
6. Test hypotheses analytically, typically with a case-control or retrospective cohort study using attack rates.
7. Implement control measures - often begun early, as soon as a plausible source is suspected.
8. Communicate findings to stakeholders and the public.

Reading the epidemic curve

The epidemic curve (or epi curve) is a histogram of case counts by time of onset, and its shape is deeply informative. A point-source outbreak, in which everyone is exposed at one time (a contaminated meal at an event), produces a single sharp peak whose spread reflects the incubation period. A continuous common-source outbreak (an ongoing contaminated water supply) shows a plateau. A propagated outbreak, spread person to person, shows a series of progressively taller peaks, each about one incubation period apart.

Attack rates point to the source

The key analytic tool in a foodborne outbreak is the attack rate: the proportion of an exposed group that becomes ill, essentially an incidence proportion for the outbreak. By computing the attack rate among those who did and did not eat each food, investigators find the item with both a high attack rate in the exposed and a large difference from the unexposed. Worked example: of 150 guests who ate the potato salad, 45 fell ill (attack rate 45 / 150 = 30 percent); of 100 who did not eat it, 5 fell ill (attack rate 5 / 100 = 5 percent). The relative risk is 0.30 / 0.05 = 6.0, strongly implicating the potato salad. The food with the largest attack-rate difference, especially when most cases ate it and few non-eaters fell ill, is the prime suspect - and removing it should end the outbreak, satisfying the Bradford Hill "experiment" viewpoint in real time.

As infectious diseases were tamed in wealthy nations, the leading causes of death shifted to chronic diseases - heart disease, cancer, stroke, diabetes, chronic lung disease - a transition called the epidemiologic transition. These diseases demand a different epidemiologic style, because their causes are slow, multiple, and entangled with behavior and society.

How chronic disease differs

Infectious disease often has a single necessary agent and a short incubation; chronic disease typically has no single cause, a long latency of years or decades, and a course measured in years. Koch's postulates, which link one microbe to one disease, simply do not apply. Instead, chronic disease epidemiology speaks of risk factors - characteristics or exposures that raise the probability of disease without being strictly necessary or sufficient. Smoking, high blood pressure, obesity, physical inactivity, and diet are risk factors, not agents; most people with a risk factor never get the disease, and some without it do.

Multifactorial causation and the web

Because many factors act together, epidemiologists picture a web of causation: an interconnected network in which distal causes (poverty, education, the built environment) influence proximal ones (diet, smoking, blood pressure), which combine to produce disease. A useful companion idea is the sufficient-component cause model, in which a disease results when a sufficient set of component causes is completed, like pieces of a pie; different people may reach the same disease by different combinations, and removing any one necessary component can prevent it. This is why chronic disease prevention has many entry points, and why no single "magic bullet" exists.

The tools: risk factors and long cohorts

The signature instrument of chronic disease epidemiology is the long-term prospective cohort study, which follows large groups for decades, measuring many exposures and awaiting many outcomes. Such studies transformed medicine by identifying major modifiable risk factors for cardiovascular disease and other chronic conditions, and they remain the backbone of the field precisely because randomizing people to lifelong exposures is impossible. Chronic disease epidemiology therefore leans heavily on the causal reasoning of Module 4: with no single agent and no possibility of a harmful-exposure trial, the Bradford Hill viewpoints applied to accumulated cohort evidence are how causation is established. The payoff is enormous, because chronic diseases are largely driven by modifiable behaviors and conditions, making them, in principle, highly preventable.

Epidemiology exists to be used. Its final purpose is action: monitoring the health of populations and turning evidence into policies that prevent disease. This closing lesson connects the science to the system that applies it.

Public health surveillance

Surveillance is the ongoing, systematic collection, analysis, and interpretation of health data, tied to timely dissemination to those who can act - famously summarized as "information for action." Passive surveillance relies on routine reporting (clinicians and laboratories notifying authorities of reportable conditions); it is inexpensive but incomplete. Active surveillance has health agencies reach out to seek cases; it is more complete but costly, and is often mounted during outbreaks. Surveillance detects epidemics early, tracks trends, evaluates whether programs work, and guides where resources should go. The measures from Module 1 - incidence, prevalence, and derived rates such as mortality and case fatality - are the currency of surveillance reports.

From evidence to policy

Sound policy rests on a hierarchy of evidence. At the base sit expert opinion and case reports; above them observational studies (cross-sectional, case-control, cohort); higher still the randomized controlled trial; and at the top the systematic review and meta-analysis, which pool many studies to yield the most reliable estimate. Bodies that issue guidelines weigh this evidence, along with cost, feasibility, and values, to produce recommendations. Deciding what a society should do also draws on cost-effectiveness analysis, which compares the health gained (often in quality-adjusted life years) against the cost of competing options, so that limited resources buy the most health.

Policy instruments and the levels of prevention

Public health acts through many levers - laws and regulation (seatbelt and clean-air laws, food safety rules), taxation (tobacco and alcohol taxes), the built environment, health education, and the direct provision of services such as vaccination and screening. Each maps onto the levels of prevention from Module 1, and the most effective often operate upstream, changing the conditions in which people live rather than relying on individual choice.

Ethics and trade-offs

Because public health acts on whole populations and sometimes constrains individuals for the common good, it is inseparable from ethics. Core tensions include individual liberty versus collective benefit (as in quarantine or vaccination mandates), the demands of justice and health equity (ensuring the burdens and benefits of policy fall fairly, and that disadvantaged groups are protected), and the duty to base coercive measures on solid evidence and the least restrictive means necessary. Epidemiology supplies the facts; a democratic society weighs them against these values. Understanding both the numbers and their limits - everything in this course - is what lets you participate in that judgment responsibly, whether as a scientist, a clinician, or a citizen.